Brief: Patient With Candida Krusei Infection In Matinas Biopharma’S Oral Mat2203 Expanded Access Program Achieves Complete Clinical Resolution
11/10/2023 12:35
Oct 11 (Reuters) - Matinas BioPharma Holdings Inc
MTNB.A :
* PATIENT WITH CANDIDA KRUSEI INFECTION IN MATINAS
BIOPHARMA’S
ORAL MAT2203 EXPANDED ACCESS PROGRAM ACHIEVES COMPLETE CLINICAL
RESOLUTION
Source text for Eikon: ID:nGNX7kcbC2
Further company coverage: MTNB.A
((Reuters.Briefs@thomsonreuters.com))
Recent news on Matinas BioPharma Holdings
See all newsBrief: GH Power Signs Multi-Year Hydrogen Offtake Agreement With Change Energy For Hamilton Facility Output
Brief: Gh Power And Tkms Continue To Explore Clean Energy Collaboration In Support Of Canada’S Future Patrol Submarine Project
Brief: Matinas Biopharma - Btig Terminates Sales Agreement With Matinas Biopharma Holdings, Effective Immediately On July 23, 2026 - SEC Filing
Brief: Matinas Biopharma Receives Notice Of Non-Compliance With NYSE American Continued Listing Standards And Acceptance Of Plan To Regain Compliance
Brief: Matinas Biopharma - May Offer Securities Up To $150 Million - SEC Filing